World’s first protease diagnostic test for chronic wounds CE marked
Systagenix has announced that WOUNDCHEK™ Protease Status has been CE marked, making it the first rapid, point-of-care diagnostic test for chronic wounds launched initially across Europe, South Africa and the Middle East.
The test assesses inflammatory protease activity in chronic wounds and identifies when there is elevated protease activity (EPA). Around 30% of non-healing chronic wounds have elevated protease activity. WOUNDCHEK™ Protease Status works in 15 minutes and is designed to help clinicians target treatment more effectively.
'Evaluation and assessment are the first steps every wound care clinician should take when presented with a chronic, hard-to-heal wound, but up until now we have not benefitted from innovation in this field,' said Keith Harding, School of Medicine, Cardiff University, UK. 'With the introduction of WOUNDCHEK™ Protease Status, Systagenix has been bold enough to invest in the field of diagnostics, and I applaud them for doing so. The effective use of a point-of-care test for protease activity has the potential to revolutionise wound care globally. This makes the WOUNDCHEK™ Protease Status test result invaluable information that clinicians will need to have on hand when evaluating and assessing chronic wounds.'
Online training tools for WOUNDCHEK™ Protease Status are available by clicking here.
Click here to see the press release.